C92, a proton channel-blocking allosteric STING agonist generates robust antitumor activity.

backgroundThe activation of stimulator of interferon genes (STING) for the treatment of cancer is a long-standing therapeutic goal. However, the clinical use of orthosteric STING agonists has shown limited utility in patients with advanced/metastatic cancer. C92 is a potent representative of a first-in-class chemical series of allosteric small-molecule human STING agonists that are distinguished by their binding site which lies within STING's proton channel and their consequently unique functional properties. This study characterizes the pharmacology and the anticancer efficacy of C92.

methodsAllosteric binding was established using radioligand binding assays. Type I interferon (IFN)-mediated immune signaling due to the activation of STING by C92 was studied in human and murine primary cells. IFN independent actions of C92 were assessed by monitoring inflammasome and autophagy markers in the human monocytic THP-1 cell line. Anticancer activity of CRD3874-SI by the intravenous route as a single agent or in combination with checkpoint inhibitors (CPIs) was evaluated in human STING knock-in C57BL/6 mice. The comparative effects of activating STING in either tumor fibroblasts or non-tumor host tissue were studied in human STING-expressing murine cells that were implanted in wt C57BL/6 and BALB/c mice.

resultsC92 is an allosteric agonist that activates STING in the absence of cyclic guanosine monophosphate-adenosine monophosphate (cGAMP). In addition, C92 can also potentiate the binding of cGAMP to STING. The allosteric binding site lies within a hydrophobic transmembrane proton channel formed by intertwined helices of two STING monomers. C92 generates strong Type I IFN responses, but without IFN-independent actions such as autophagy and inflammasome formation. Intravenous, oral or intratumoral administration of C92 as a single agent led to robust antitumor immune responses and synergized with CPI treatment providing a path for the clinical translation of C92. The unique species selectivity profile of C92 enabled a demonstration that anticancer effects can be mediated by STING either in tumor cells or in non-tumor host cells.

conclusionThe allosteric small-molecule human STING agonist C92 that blocks STING's proton channel is significantly differentiated from orthosteric STING agonists by its unique pharmacology making it a promising immune therapeutic for the treatment of cancer.